This newer mode of administration for immunotherapy comes with benefits and risks. It is important for a person to work with a doctor when making treatment decisions for upper gastrointestinal (GI) ...

Cosentyx (secukinumab) comes as a subcutaneous injection under the skin or an intravenous (IV) infusion into a vein. Doctors may prescribe it to treat plaque psoriasis, psoriatic arthritis, and other ...

Stelara (ustekinumab) is a brand-name prescription drug approved to treat Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. You should always administer Stelara according ...

Learn about switching from IVIg to SCIg for CIDP, including benefits, barriers, and support for home-based subcutaneous ...

Saphnelo (anifrolumab) is a medicine used to treat systemic lupus erythematosus (SLE). Lupus is a long-term autoimmune condition in which the immune system attacks the body’s healthy tissues. Saphnelo ...

The subcutaneous formulation of Opdivo Qvantig reduces administration time to three to five minutes, compared to 30 minutes for the IV version. This formulation offers increased convenience, ...

Switching from IV to subcutaneous injection eases hard vein access, cuts clinic time, and boosts comfort with faster treatment and fewer side effects. In this segment, Ms. Haupert shares her personal ...

Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myelomaApproval based on multiple studies, including the ...

The US Food and Drug Administration (FDA) has approved the biologics license application for a subcutaneous formulation of lecanemab (Leqembi Iqlik) for weekly maintenance dosing to treat Alzheimer’s ...

Panelists discuss how integrating both intravenous (IV) and subcutaneous (SubQ) therapies in oncology centers requires adaptable staffing, data-driven workflow planning, and thoughtful pilot ...

MILAN -- An investigational 10-minute subcutaneous injection of ocrelizumab (Ocrevus) was non-inferior to the established IV infusion formulation of the drug in multiple sclerosis (MS), the phase III ...